12:00 AM
 | 
Mar 05, 2012
 |  BC Week In Review  |  Company News  |  Deals

Galapagos, Abbott deal

The companies partnered to develop and commercialize Galapagos' GLPG0634, a Janus kinase-1 (JAK-1) inhibitor in Phase II testing for rheumatoid arthritis. Galapagos will receive $150 million up front. If the...

Read the full 149 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >